Efficacy and safety of thymosin combined with anticancer therapy for colorectal cancer: a systematic review and meta-analysis of controlled studies
- 1Department of Oncology, the First Affiliated Hospital of Henan University of Chinese Medicine
- 2Henan University of Chinese Medicine
- 3Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine
Abstract
Objective: To evaluate the efficacy and safety of thymosin preparations added to the same background anticancer treatment in patients with colorectal cancer.
Methods: We searched nine bibliographic and trial-registration sources through 1 October 2026. Randomized controlled trials (RCTs) and nonrandomized studies with concurrent controls were eligible. Risk of bias was assessed using RoB 2 and ROBINS-I. RCTs provided the primary evidence; nonrandomized studies were analyzed separately. Review Manager 5.4.1 calculated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs), organized by treatment setting. Sensitivity analyses, GRADE and exploratory trial sequential analysis (TSA) assessed robustness and uncertainty.
Results: Thirty studies involving 2,514 participants comprised 25 RCTs (2,079 participants) and five nonrandomized studies (435 participants). In postoperative RCTs, CD4 percentage (MD 6.33, 95% CI 4.89 to 7.76), CD4/CD8 ratio (MD 0.25, 0.16 to 0.35) and NK-cell percentage (MD 6.41, 3.72 to 9.11) were higher with thymosin; CD3 and CD8 findings were inconclusive. KPS was higher in two postoperative RCTs (MD 8.50, 6.52 to 10.48) and two advanced or mixed-stage trials (MD 4.35, 1.90 to 6.80), with source-reporting concerns affecting the latter. Postoperative neutropenia was inconclusive in the RCT (RR 0.91, 0.82 to 1.01), whereas two nonrandomized studies reported a lower unadjusted risk (RR 0.65, 0.51 to 0.83). Comparable one-year survival evidence came from one trial. Certainty was low or very low.
Conclusion: This review identifies RCT-based signals in circulating immune indices and performance status and clarifies the contribution of nonrandomized evidence. These findings inform the selection of outcomes and treatment settings for future trials. Current evidence is insufficient to support routine clinical use of thymosin preparations in colorectal cancer.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261467566 , CRD420261467566.
Related
- Comparative efficacy of common adjuvant treatments after resection of colorectal liver metastases : A systematic review and network meta-analysis
- The Role of Intraoperative Indocyanine Green Fluorescence Angiography in Reducing Anastomotic Leak After Colorectal Resection: A Systematic Review of Randomised Controlled Trials
- Optimizing Indocyanine Green Fluorescence Cholangiography in Laparoscopic Cholecystectomy: A Systematic Review of Randomized Controlled Trials on Dose, Timing, Route, Efficacy, and Safety
- Efficacy and safety of bone marrow aspirate and bone marrow aspirate concentrate in orthopedic conditions: a systematic review of randomized controlled trials
- Efficacy and Safety of Tegoprazan–Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis With Trial Sequential Analysis of Randomized Controlled Trials
BibTeX
@article{zhang2026efficacy,
title = {{Efficacy and safety of thymosin combined with anticancer therapy for colorectal cancer: a systematic review and meta-analysis of controlled studies}},
author = {Guannan Zhang and Yuxin Zhou and Tao Sun and Xiaoqi Chen and Yuling Zheng},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1957041},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1957041/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Efficacy and safety of thymosin combined with anticancer therapy for colorectal cancer: a systematic review and meta-analysis of controlled studies
AU - Guannan Zhang
AU - Yuxin Zhou
AU - Tao Sun
AU - Xiaoqi Chen
AU - Yuling Zheng
PY - 2026
DA - 2026/10/29
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1957041
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1957041/full
AB - Objective: To evaluate the efficacy and safety of thymosin preparations added to the same background anticancer treatment in patients with colorectal cancer. Methods: We searched nine bibliographic and trial-registration sources through 1 October 2026. Randomized controlled trials (RCTs) and nonrandomized studies with concurrent controls were eligible. Risk of bias was assessed using RoB 2 and ROBINS-I. RCTs provided the primary evidence; nonrandomized studies were analyzed separately. Review Manager 5.4.1 calculated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs), organized by treatment setting. Sensitivity analyses, GRADE and exploratory trial sequential analysis (TSA) assessed robustness and uncertainty. Results: Thirty studies involving 2,514 participants comprised 25 RCTs (2,079 participants) and five nonrandomized studies (435 participants). In postoperative RCTs, CD4 percentage (MD 6.33, 95% CI 4.89 to 7.76), CD4/CD8 ratio (MD 0.25, 0.16 to 0.35) and NK-cell percentage (MD 6.41, 3.72 to 9.11) were higher with thymosin; CD3 and CD8 findings were inconclusive. KPS was higher in two postoperative RCTs (MD 8.50, 6.52 to 10.48) and two advanced or mixed-stage trials (MD 4.35, 1.90 to 6.80), with source-reporting concerns affecting the latter. Postoperative neutropenia was inconclusive in the RCT (RR 0.91, 0.82 to 1.01), whereas two nonrandomized studies reported a lower unadjusted risk (RR 0.65, 0.51 to 0.83). Comparable one-year survival evidence came from one trial. Certainty was low or very low. Conclusion: This review identifies RCT-based signals in circulating immune indices and performance status and clarifies the contribution of nonrandomized evidence. These findings inform the selection of outcomes and treatment settings for future trials. Current evidence is insufficient to support routine clinical use of thymosin preparations in colorectal cancer. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261467566 , CRD420261467566.
SN - 2234-943X
ER -